Danielle Hammond, MD
Department of Leukemia, Division of Cancer Medicine
About Dr. Danielle E Hammond
Dr. Hammond is a Canadian-trained hematologist and Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. As a clinician-investigator in the Myelodysplastic Syndromes Section, she co-leads the Clonal Hematopoiesis and Leukemia Prevention Clinic, focused on risk-adapted early-intervention strategies for individuals with at-risk clonal hematopoiesis. She also leads a multidisciplinary effort to provide comprehensive evaluation and management for patients with clonal hematologic disorders complicated by autoinflammatory manifestations, with particular expertise in VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome
Present Title & Affiliation
Primary Appointment
Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2014 | University of Ottawa, Ottawa, CA, MD |
Postgraduate Training
| 2019-2021 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2019 | Clinical Residency, Adult Hematology, Queen's University, Kingston |
| 2014-2017 | Clinical Residency, Internal Medicine, University of Toronto, Toronto |
Licenses & Certifications
| 2021 | Faculty Temporary License |
| 2021 | Texas Medical Board, MDACC Sponsored Faculty Temporary Permit |
| 2019 | The Royal College of Physicians and Surgeons of Canada Certification in Adult Hematology |
| 2018 | The Royal College of Physicians and Surgeons of Canada Certification in Internal Medicine |
| 2016 | Licentiate, Medical Council of Canada |
| 2014 | United States Medical Licensing Exam, Step 2 Clinical Knowledge |
Experience & Service
Other Professional Positions
Professional Member, MDS Foundation, 2025 - Present
Working Group Member, International MDS Guidelines, 2023 - 2025
Chief Leukemia Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2021
Co-chief Hematology Resident, Queen’s University, Kingston, 2018 - 2019
Honors & Awards
| 2023 - Present | Physicians Referral Service and Patient Experience Recognition |
| 2022 - Present | Waun Ki Hong Award for Excellence in Team Science, Clonal Hematopoiesis Team, The University of Texas MD Anderson Cancer Center |
| 2021 | Best Overall Fellow, Leukemia Fellowship Program 2020-2021, The University of Texas MD Anderson Cancer Center |
| 2021 | ASCO 2021 Conquer Cancer Abstract Merit Award, ASCO |
| 2020 | ASH 2020 Abstract Achievement Award, ASH |
| 2020 | Best Clinical Fellow, Leukemia Fellowship Program 2019-2020, The University of Texas MD Anderson Cancer Center |
| 2018 | Resident Prize for Excellence in Undergraduate Teaching, Nominee, Queen’s University, Kingston, ON |
| 2018 | Canadian National Hematology Trainee Quality Improvement Award |
| 2017 | Alexion Canada Honorarium, Canadian Fellows Program, ASH 2017 Annual General Meeting, Atlanta, GA |
| 2017 | Department of Medicine Teaching Award, Sunnybrook Health Sciences Centre, Toronto, ON |
| 2013 | Outstanding Clinical Performance, Core Internal Medicine Clerkship Rotation, The Ottawa General Hospital, Ottawa, ON |
| 2013 | Physician Kudos Award, The Ottawa General Hospital, Ottawa, ON |
| 2010 | J.A.F. Stevenson Medal, Western University, London, ON |
| 2008 | New Member of the Year, Science Students’ Council, Western University, London, ON |
| 2006 | Dr. D. Carlton Williams President's Entrance Scholarship, Western University, London, ON |
Selected Presentations & Talks
Local Presentations
- 2022. Clonal hematpoiesis of emerging significance: an introduction to the MD Anderson CHIP and Leukemia Prevention Clinic. Conference. Clonal hematpoiesis of emerging significance: an introduction to the MD Anderson CHIP and Leukemia Prevention Clinic. Houston, TX, US.
- 2022. DoCM Grand Rounds July 26, 2022: Clonal hematpoiesis of emerging significance: an introduction to the MD Anderson CHIP and Leukemia Prevention Clinic. Conference. DoCM Grand Rounds July 26, 2022: Clonal hematpoiesis of emerging significance: an introduction to the MD Anderson CHIP and Leukemia Prevention Clinic. Houston, TX, US.
Grant & Contract Support
| Date: | 2021 - Present |
| Title: | Measurable residual disease detection using single-cell multiomics in patients with acute myeloid leukemia |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Title: | 2022-0187: A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis |
| Funding Source: | Pulmocide |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Chien KS, Loghavi S, Sasaki K, McCue D, Daver NG, Kadia TM, Ravandi F, Short NJ, Issa GC, Montalban-Bravo G, Haddad FG, Hammond DE, Swaminathan M, Bazinet A, Bataller A, Bouligny I, Pierce SA, Garcia-Manero G, Kantarjian HM, DiNardo CD. Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib. Clin Lymphoma Myeloma Leuk 26(2):e223-e228.e3, 2026. e-Pub 2026. PMID: 41469316.
- Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Davis, JA, Hou, H, Jain, A, Malovannaya, A, Flores, L, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Wang, J, Loghavi, S, Su, X, DiNardo, C, Delwel, R, Bhalla, K. Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. HemaSphere 10(1), 2026. e-Pub 2026. PMID: 41551728.
- Azevedo, RS, Jen, WY, Hammond, DE, Haddad, FG, Geppner, A, Issa, GC, Sasaki, K, Senapati, J, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell/myeloid mixed phenotype acute leukemia. Haematologica 110(12):3129-3132, 2025. e-Pub 2025. PMID: 40568715.
- Bataller Torralba, A, Sasaki, K, Urrutia, S, Montalban Bravo, G, Bazinet, A, Chien, KS, Hammond, DE, Bouligny, IM, Swaminathan, M, Issa, GC, Short, NJ, Daver, N, DiNardo, C, Kadia, TM, Jabbour, EJ, Ravandi-Kashani, F, Roboz, G, Savona, MR, Griffiths, EA, McCloskey, J, Odenike, O, Oganesian, A, Keer, HN, Azab, M, Kantarjian, HM, Garcia-Manero, G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40164584.
- Loghavi, S, Abdel-Salam, HM, Hammond, DE, Chien, KS, Patel, KP, Arun, BK, DiNardo, C. Unveiling the Origins of Pathogenic TP53 Variants in Clinical Context. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40991881.
- Montalban Bravo, G, Loghavi, S, Li, Z, Chien, KS, Kanagal Shamanna, R, Bataller Torralba, A, Natu, A, Gurney, M, Bazinet, A, Hammond, DE, Sasaki, K, Borthakur, G, Swaminathan, M, DiNardo, C, Kadia, TM, Ravandi-Kashani, F, Daver, N, Short, NJ, Pemmaraju, N, Issa, GC, Lasho, T, Finke, C, Al-Kali, A, Csizmar, C, Alkhateeb, HB, Gangat, N, Mangaonkar, AA, Bueso-Ramos, CE, Tefferi, A, Kantarjian, HM, Garcia-Manero, G, Patnaik, MM. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. Blood Advances 9(19):5105-5117, 2025. e-Pub 2025. PMID: 40644618.
- Jen, WY, Croden, J, Almanza-Huante, E, DiNardo, C, Chien, KS, Hammond, DE, Qiao, W, Alvarado, Y, Masarova, L, Quesada, AE, Pierce, S, Bataller Torralba, A, Garcia-Manero, G, Alousi, AM, Short, NJ, Daver, N, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia. HemaSphere 9(10), 2025. e-Pub 2025. PMID: 41132245.
- Bazinet, A, Loghavi, S, Wei, Y, Bataller Torralba, A, Sasaki, K, Arani, N, Darbaniyan, F, Chien, KS, Hammond, DE, Bouligny, IM, Kanagal Shamanna, R, Thongon, N, Tang, G, Urrutia, S, Kadia, TM, DiNardo, C, Daver, N, Short, NJ, Issa, GC, Pemmaraju, N, Jabbour, EJ, Wang, S, Wang, W, Borthakur, G, Bueso-Ramos, CE, Ravandi-Kashani, F, Medeiros, LJ, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256-2265, 2025. e-Pub 2025. PMID: 40691503.
- DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol 43(24):2692-2699, 2025. e-Pub 2025. PMID: 40513054.
- Tefferi, A, Fathima, S, Abdelmagid, M, Alsugair, AA, Aperna, F, Rezasoltani, M, Yousuf, M, Natu, A, Csizmar, C, Gurney, M, Lasho, T, Finke, C, Kangal-Shamanna, R, Hammond, DE, Chien, KS, Bazinet, A, DiNardo, C, Kadia, TM, Mangaonkar, AA, Daver, N, Pardanani, A, Borthakur, G, Zepeda-Mendoza, CJ, Reichard, KK, He, R, Loghavi, S, Passamonti, F, Ravandi-Kashani, F, Sasaki, K, Larson, DR, Garcia-Manero, G, Onida, F, Gangat, N, Montalban Bravo, G, Patnaik, MM. BLAST. Blood 146(7):874-886, 2025. e-Pub 2025. PMID: 40332442.
- Csizmar, C, Natu, A, Gurney, M, Fathima, S, Alsugair, AA, Kanagal Shamanna, R, Loghavi, S, Bazinet, A, Chien, KS, Hammond, DE, DiNardo, C, Kadia, TM, Ravandi-Kashani, F, Pemmaraju, N, Sasaki, K, Lasho, T, Finke, C, Al-Kali, A, Alkhateeb, HB, Begna, K, Gangat, N, Hefazi Torghabeh, M, Matin, A, Mangaonkar, AA, Saliba, AN, Tefferi, A, Garcia-Manero, G, Kantarjian, HM, Komrokji, RS, Xie, Z, Ali, NA, Sallman, D, Padron, E, Montalban Bravo, G, Patnaik, MM. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia 39(8):2030-2034, 2025. e-Pub 2025. PMID: 40555734.
- Senapati, J, Loghavi, S, Garcia-Manero, G, Tang, G, Kadia, TM, Short, NJ, Abbas, HA, Arani, N, DiNardo, C, Borthakur, G, Pemmaraju, N, Oran, B, Shpall, E, Popat, UR, Champlin, RE, Pierce, S, Arora, S, Issa, GC, Yilmaz, M, Patel, KP, Takahashi, K, Montalban Bravo, G, Hammond, DE, Haddad, FG, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2025. e-Pub 2025. PMID: 39665206.
- Marvin-Peek, J, Shelton, V, Brassil, KJ, Fellman, B, Barr, A, Chien, KS, Hammond, DE, Swaminathan, M, Jain, N, Wierda, WG, Ferrajoli, A, DiNardo, C. Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia. Acta haematologica 148(2):233-243, 2025. e-Pub 2025. PMID: 38861934.
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- Gener-Ricos, G, Bataller, A, Rodriguez-Sevilla, JJ, Chien, KS, Quesada, AE, Almanza-Huante, E, Hammond, DE, Sasaki, K, DiNardo, C, Kadia, TM, Daver, N, Borthakur, G, Issa, GC, Short, NJ, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
- Sasaki, K, Kantarjian, HM, Montalban Bravo, G, Hammond, DE, Jabbour, EJ, Kanagal Shamanna, R, Chien, KS, Garcia-Manero, G. Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 24(9):629-633, 2024. e-Pub 2024. PMID: 38777652.
- Montalban Bravo, G, Jabbour, EJ, Chien, KS, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Konopleva, M, Borthakur, G, Daver, N, Kanagal-Shammana, R, Loghavi, S, Qiao, W, Huang, X, Schneider, H, Meyer, M, Kantarjian, HM, Garcia-Manero, G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leukemia Research 142, 2024. e-Pub 2024. PMID: 38744144.
- Bataller, A, Gener-Ricos, G, Almanza-Huante, E, Chien, KS, Urrutia, S, Bazinet, A, Rodriguez-Sevilla, JJ, Hammond, DE, Sasaki, K, Takahashi, K, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Kadia, TM, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Advances 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
- Fiskus, WC, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Mill, CP, Birdwell, C, Das, K, Davis, JA, Hou, H, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Reville, PK, Wang, J, Loghavi, S, Sen, R, Ruan, X, Su, X, Flores, L, DiNardo, C, Bhalla, K. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood 143(20):2059-2072, 2024. e-Pub 2024. PMID: 38437498.
- Bazinet, A, Desikan, SP, Li, Z, Rodriguez-Sevilla, JJ, Venugopal, S, Urrutia, S, Montalban Bravo, G, Sasaki, K, Chien, KS, Hammond, DE, Kanagal Shamanna, R, Ganan Gomez, I, Kadia, TM, Borthakur, G, DiNardo, C, Daver, N, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clinical Cancer Research 30(7):1319-1326, 2024. e-Pub 2024. PMID: 38300723.
- Bataller, A, Montalban Bravo, G, Bazinet, A, Alvarado, Y, Chien, KS, Venugopal, S, Ishizawa, J, Hammond, DE, Swaminathan, M, Sasaki, K, Issa, GC, Short, NJ, Masarova, L, Daver, N, Kadia, TM, Colla, S, Qiao, W, Huang, X, Kanagal Shamanna, R, Hendrickson, S, Ravandi-Kashani, F, Jabbour, EJ, Kantarjian, HM, Garcia-Manero, G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. The Lancet Haematology 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
- Montalban Bravo, G, Jabbour, EJ, Borthakur, G, Kadia, TM, Ravandi-Kashani, F, Chien, KS, Pemmaraju, N, Hammond, DE, Dong, XQ, Huang, X, Schneider, H, John, RB, Kanagal-Shamana, R, Loghavi, S, Kantarjian, HM, Garcia-Manero, G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. British Journal of Haematology 204(3):898-909, 2024. e-Pub 2024. PMID: 37946611.
- Chien, KS, Ong, F, Kim, K, Li, Z, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Montalban Bravo, G, Hammond, DE, Sasaki, K, Pierce, SA, Kantarjian, HM, Garcia-Manero, G. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer medicine 13(5), 2024. e-Pub 2024. PMID: 38497538.
- Chiu CY, Matsuo T, Wurster S, Gerstein Y, Hammond DE, Chien KS, DiNardo C, Kontoyiannis DP. Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency. Mycoses 66(12):1029-1034, 2023. e-Pub 2023. PMID: 37550272.
- Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
- Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, Kadia, TM, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American journal of hematology 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
- Montalban Bravo, G, Kanagal Shamanna, R, Li, Z, Hammond, DE, Chien, KS, Rodriguez-Sevilla, JJ, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
- Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica 108(9):2331-2342, 2023. e-Pub 2023. PMID: 36951163.
- DiNardo CD, Venugopal S, Lachowiez CA, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway HE, Sekeres MA, Sukkur A, Hammond D, Chien KS, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia TM, Short NJ, Daver NG, Borthakur G, Ravandi F, Kantarjian HM, Patel BJ, DeZern AE, Roboz GJ, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2022. PMID: 35973199.
- Gener-Ricos, G, Gerstein, YS, Hammond, DE, DiNardo, C. Germline Predisposition to Myelodysplastic Syndromes. Cancer Journal (United States) 29(3):143-151, 2023. e-Pub 2023. PMID: 37195770.
- Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. Am J Hematol 98(4):E91-E94, 2023. e-Pub 2023. PMID: 36661399.
- Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2023. PMID: 36458426.
- Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
- Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
- Ong, F, Kim, K, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Kadia, TM, Jabbour, EJ, Short, NJ, Hammond, DE, Pemmaraju, N, Pierce, S, Montalban Bravo, G, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH). Clinical Lymphoma, Myeloma and Leukemia 22:S319, 2022. e-Pub 2022. PMID: 36163972.
- Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S313-S314, 2022. e-Pub 2022. PMID: 36163960.
- Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S311, 2022. e-Pub 2022. PMID: 36163957.
- Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, Pollyea DA, DiNardo CD, Wei AH. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv 6(13):3879-3883, 2022. e-Pub 2022. PMID: 35511730.
- Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2021. PMID: 33156969.
- Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of Venetoclax-Based Therapy in Chronic Myelomonocytic Leukemia. Leukemia, 2021. e-Pub 2021. PMID: 33846541.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia, 2020. e-Pub 2020. PMID: 33156969.
- Lamarche MC, Hammond D, Hopman W, Sirosky, #8208, Yanyk A, Shepherd L, Bhella SD. Can We Transfuse Wisely in Patients Undergoing Chemotherapy for Acute Leukemia or Autologous Stem Cell Transplantation?. Transfusion 59(7):2308-2315, 2019. e-Pub 2019. PMID: 31059586.
- Gándara E, Hammond D, Nagpal S. Role of Vitamin K Antagonists in the Prevention of Thrombotic Bypass Occlusion After Infrainguinal Venous Bypass, 2016. e-Pub 2016. PMID: 27142190.
- Mouhayar E, Hammond D, Lopez-Mattei J, Banchs J, Konopleva M, Pemmaraju N. . Reversible Myocardial Edema Secondary to Tagraxofusp-induced Capillary Leak Syndrome. JACC: CardioOncology.
Invited Articles
- Hammond D, Loghavi S. Clonal Haematopoiesis of Emerging Significance, 2021. e-Pub 2021. PMID: 33685721.
- Hammond D, Montalban-Bravo G. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia, 2021. e-Pub 2021.
- Hammond D, Pemmaraju N. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm, 2020. e-Pub 2020. PMID: 32336420.
Review Articles
- Haque, T, Shastri, A, Desai, PM, Xie, Z, Hammond, DE, King, Z, Kishtagari, A, Madanat, Y, Abaza, YM, Silver, AJ, Singh, A, Borate, U, Heimlich, JB, Slosky, D, Bolton, KL, Patnaik, MM, Bick, AG, Verma, AK, Jaiswal, S, Steensma, DP, Savona, MR. A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis. British Journal of Haematology 206(2):416-427, 2025. e-Pub 2025. PMID: 39653653.
- Cuglievan, B, Connors, JS, He, J, Khazal, SJ, Yedururi, S, Dai, J, Garces, S, Quesada, AE, Roth, M, Garcia, M, McCall, DC, Gibson, A, Ragoonanan, D, Petropoulos, D, Tewari, P, Nunez, CA, Mahadeo, KM, Tasian, SK, Lamble, AJ, Pawlowska, A, Hammond, DE, Maiti, A, Haddad, FG, Senapati, J, Daver, N, Gangat, N, Konopleva, M, Meshinchi, S, Pemmaraju, N. Blastic plasmacytoid dendritic cell neoplasm. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
- Vuong, NN, Hammond, DE, Kontoyiannis, DP. Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease. Journal of Fungi 9(4), 2023. e-Pub 2023. PMID: 37108918.
- Santanelli di Pompeo F, Clemens MW, Atlan M, Botti G, Cordeiro PG, De Jong D, Di Napoli A, Hammond D, Haymaker CL, Horwitz SM, Hunt K, Lennox P, Mallucci P, Miranda RN, Munhoz AM, Swanson E, Turner SD, Firmani G, Sorotos M. 2022 Practice Recommendation Updates From the World Consensus Conference on BIA-ALCL. Aesthet Surg J 42(11):1262-1278, 2022. e-Pub 2022. PMID: 35639805.
- Mouhayar EN, Hammond D, Lopez-Mattei J, Banchs J, Konopleva M, Pemmaraju N. Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome. JACC CardioOncol 3(5):752-755, 2021. e-Pub 2021. PMID: 34988487.
- Hammond D, Montalban-Bravo G. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia. Curr Hematol Malig Rep 16(5):405-417, 2021. e-Pub 2021. PMID: 34499330.
- Hammond D, Loghavi S. Clonal haematopoiesis of emerging significance. Pathology 53(3):300-311, 2021. e-Pub 2021. PMID: 33685721.
- Hammond D, Pemmaraju N. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am 34(3):565-574, 2020. e-Pub 2020. PMID: 32336420.
Abstracts
- Hammond D, Sasaki K, Geppner A, Haddad F, Mohamed S, Rivera D, Siddiqui M, Alwash Y, Ramos Perez J, Morita K, Kim K, Pierce S, Gutierrez C, Pemmaraju N, Borthakur G, Dinardo CD, Ravandi F, Garcia-Manero G, Kantarjian H, Kadia TM. Contemporary Outcomes for Adults with AML Requiring ICU Admission, 2021. e-Pub 2021.
- Chua CC, Hammond D, Kent A, Tiong IS, Ong DM, Konopleva M, Pollyea D, Dinardo CD, Wei AH. Treatment Free Remission After Ceasing Venetoclax-based Therapy in Responding Patients with Acute Myeloid Leukemia, 2021. e-Pub 2021.
- Hammond D, Kadia TM, DiNardo CD, Konopleva M, Short NJ, Daver N, Ravandi F, Pemmaraju N, Jabbour E, Chien K, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia, 2021. e-Pub 2021.
- Guerra V, Ramos Perez J, Hammond D, Chien K, Kanagal-Shamanna R, Naqvi K, Sasaki K, Paul S, Kadia TM, DiNardo CD, Konopleva M, Daver N, Ravandi F, Pemmaraju N, Short NJ, Issa GC, Takahashi K, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Outcomes of Chronic Myelomonocytic Leukemia after Hypomethylating Agent Failure, 2020. e-Pub 2020.
- Hammond D, Loghavi S, Konopleva M, Kadia TM, Daver N, Ohanian M, Issa GC, Alvarado Y, Montalban-Bravo G, Garcia-Manero G, Borthakur G, Ravandi F, Takahashi K, Kantarjian H, DiNardo CD. Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents, 2020. e-Pub 2020.
- Hammond D, DiNardo CD, Konopleva M, Borthakur G, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Paul S, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation, 2020. e-Pub 2020.
- Teichman J, Hammond D, Fenech S, Sholzberg M. Effect of Direct Oral Anticoagulants on Fibrinogen Induced Pseudoparaproteinemia, 2018. e-Pub 2018.
- Hammond D, Jamali M, Wells RA, Zhang L, Mamedov A, Lenis M, Buckstein R. Impact of Bone Marrow Fibrosis in MDS Patients Treated with Azacitidine, 2016. e-Pub 2016.
- Hammond D, Saidenberg E, Tinmouth A. Single Centre Experience with Rituximab in the Treatment of Inhibitor‐Associated Hemostatic Disorders, 2015. e-Pub 2015.
- Hammond D, Saidenberg E, Tinmouth A. Single Centre Experience with Rituximab in the Treatment of Inhibitor‐Associated Hemostatic Disorders, 2015. e-Pub 2015.
Letters to the Editor
- Bazinet, A, Montalban Bravo, G, Bataller Torralba, A, Hammond, DE, Loghavi, S, Chien, KS, Sasaki, K, Bouligny, IM, Swaminathan, M, Jen, WY, Popat, UR, Kadia, TM, DiNardo, C, Jabbour, EJ, Short, NJ, Daver, N, Ravandi-Kashani, F, Garcia-Manero, G. Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome. Leukemia 39: 2820-2824, 2025.
- Croden, J, Jen, WY, Marvin-Peek, J, Xiao, L, Bouligny, IM, Loghavi, S, Borthakur, G, Daver, N, Abbas, HA, Takahashi, K, Sasaki, K, Pemmaraju, N, Short, NJ, Hammond, DE, Jabbour, EJ, Masarova, L, Chien, KS, Issa, GC, Montalban Bravo, G, Yilmaz, M, Maiti, A, Alvarado, Y, Garcia-Manero, G, Ravandi-Kashani, F, Konopleva, M, Kantarjian, HM, Kadia, TM, DiNardo, C. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia 39: 2538-2541, 2025.
- Tremblay, D, Csizmar, C, DiNardo, C, Ball, S, Rippel, N, Hammond, DE, Kadia, TM, Ravandi, F, Chien, KS, Van Hyfte, G, Mazumdar, M, Saliba, AN, Mangaonkar, AA, Lasho, T, Al-Kali, A, Kremyanskaya, M, Feld, J, Silverman, LR, Komrokji, RS, Mascarenhas, J, Padron, E, Garcia-Manero, G, Sallman, D, Patnaik, MM, Montalban Bravo, G. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia. Leukemia 39: 257-260, 2025.
- Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce SA, Huang X, Jabbour EJ, Kantarjian HM, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res 147: 107602, 2024.
- Csizmar, C, Gurney, M, Kanagal-Shamanna, R, Chien, KS, Hammond, DE, Lasho, T, Finke, C, Dean, C, Natu, A, Mangaonkar, AA, Al-Kali, A, Gangat, N, Tefferi, A, Alkhateeb, HB, Garcia-Manero, G, Komrokji, RS, Ali, NA, Padron, E, Montalban Bravo, G, Patnaik, MM. ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica 109: 3419-3425, 2024.
- Wei, Y, Zheng, H, Li, Z, Lockyer, P, Darbaniyan, F, Kanagal-Shamanna, R, Yang, H, Hammond, DE, Garcia-Manero, G. Downregulation of UBA1 expression in myelodysplastic neoplasm. Leukemia 38: 2284-2288, 2024.
- Nasnas, PE, Ling, J, Gerstein, YS, Wang, S, Loghavi, S, Hammond, DE, Montalban Bravo, G, Senapati, J, Pemmaraju, N, Corredor, J, Pierce, S, Roth, M, Ravandi-Kashani, F, Cuglievan, B, Kadia, TM, DiNardo, C. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes. Clinical Lymphoma, Myeloma and Leukemia 24: 732-735, 2024.
- Montalban Bravo, G, Rodriguez-Sevilla, JJ, Swanson, DM, Kanagal Shamanna, R, Hammond, DE, Chien, KS, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
- Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.
Patient Reviews
CV information above last modified July 22, 2026